Lawrence Sarah L, Roth Virginia, Slinger Robert, Toye Baldwin, Gaboury Isabelle, Lemyre Brigitte
Department of Obstetrics, Gynecology and Newborn Care, The Ottawa Hospital, Ottawa, Ontario, Canada.
BMC Pediatr. 2005 Dec 23;5:49. doi: 10.1186/1471-2431-5-49.
Coagulase negative staphylococcus (CONS) is the main cause of late-onset sepsis in Neonatal Intensive Care Units (NICU). Although CONS rarely causes fulminant sepsis, vancomycin is frequently used as empiric therapy. Indiscriminate use of vancomycin has been linked to the emergence of vancomycin resistant organisms. The objective of this study was to compare duration of CONS sepsis and mortality before and after implementation of a policy of selective vancomycin use and compare use of vancomycin between the 2 time periods.
A retrospective study was conducted of infants > or =4 days old, experiencing signs of sepsis with a first positive blood culture for CONS, during two 12-month periods. Late-onset sepsis was treated empirically with vancomycin and gentamicin during period 1, and cloxacillin and gentamicin during period 2. The confidence interval method was used to assess non-inferiority of the outcomes between the two study groups.
There were 45 episodes of CONS sepsis during period 1 and 37 during period 2. Duration of sepsis was similar between periods (hazard ratio of 1.00, 95%CI: 0.64, 1.57). One death during period 2 was possibly related to CONS sepsis versus none in period 1. Vancomycin was used in 97.8% of episodes in period 1 versus 81.1% of episodes in period 2.
Although we failed to show non-inferiority of duration of sepsis in the cloxacillin and gentamicin group compared to the vancomycin and gentamicin group, duration of sepsis was clinically similar. Restricting vancomycin for confirmed cases of CONS sepsis resistant to oxacillin appears effective and safe, and significantly reduces vancomycin use in the NICU.
凝固酶阴性葡萄球菌(CONS)是新生儿重症监护病房(NICU)晚发性败血症的主要病因。尽管CONS很少引起暴发性败血症,但万古霉素仍经常被用作经验性治疗药物。万古霉素的滥用与耐万古霉素菌株的出现有关。本研究的目的是比较在实施选择性使用万古霉素政策前后CONS败血症的病程和死亡率,并比较两个时间段内万古霉素的使用情况。
对两个12个月期间内年龄≥4天、出现败血症体征且首次血培养CONS呈阳性的婴儿进行回顾性研究。在第1阶段,晚发性败血症经验性使用万古霉素和庆大霉素治疗,在第2阶段则使用氯唑西林和庆大霉素治疗。采用置信区间法评估两个研究组之间结果的非劣效性。
第1阶段有45例CONS败血症发作,第2阶段有37例。两个阶段败血症的病程相似(风险比为1.00,95%置信区间:0.64,1.57)。第2阶段有1例死亡可能与CONS败血症有关,而第1阶段无死亡病例。第1阶段97.8%的发作使用了万古霉素,第2阶段为81.1%。
尽管我们未能证明氯唑西林和庆大霉素组败血症病程相对于万古霉素和庆大霉素组具有非劣效性,但败血症病程在临床上相似。将万古霉素的使用限制于确诊的对苯唑西林耐药的CONS败血症病例似乎有效且安全,并显著减少了NICU中万古霉素的使用。